Transition Cell CancerNCT06729346
Is the Normal Looking Bladder Mucosa on WL Cystoscopy During TURBT Really Normal and Can NBI Detect Hidden Tumor
An observational study of Transition Cell Cancer, run by Armed Forces Institute of Urology, Rawalpindi at 2 sites in Pakistan.
Trial summary
As every urologist does transurethral resection of bladder tumor. So there are instances in which the operating surgeon is not sure whether the normal-looking mucosa or the inflammatory changes are really benign or if we are missing the CIS/bladder cancer. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Transition Cell Cancer
- How many people
- 100 participants
- Where
- 2 sitesPakistan
- Study dates
- 28 Dec 2024to 30 Mar 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: any patient who presented with armed forces institute of urology with bladder tumor .
Who may be able to join
- any patient with bladder tumor
- -
Who cannot join
- any patient whose age is less than 18 years any patient whose age is more than 75 years
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
ullah contact
Pakistan2 sites, 2 recruiting
- Recruiting
Armed Forces Institute of Urology
Rawalpindi, Punjab Province, 46000
azmat ullah, consultant urologist, +923329354338, azmatdawar254@gmail.com
azmat ullah
- Recruiting
Armed Forces Institute of Urology
Rawalpindi, Punjab Province, 46020
azmat ullah, +923329354338, azmatdawar254@gmail.com
azmat ullah, consultant urologist, +923329354338, azmatdawar254@gmail.com
About this study
Official title: Can Narrow-band Imaging Detect CIS/Tumor in Normally Looking Bladder Mucosa on White Light Cystoscopy During Transurethral Resection of Bladder Tumor?
As every urologist does transurethral resection of bladder tumor. So there are instances in which the operating surgeon is not sure whether the normal-looking mucosa or the inflammatory changes are really benign or if we are missing the CIS/bladder cancer.
Read the detailed description
This is basically the observational study. in which we want to clarify that the normal-looking mucosa on white light cystoscopy is normal in reality or we are missing CIS/bladder tumor.
- Conditions
- Transition Cell Cancer
What is being measured
The primary outcome is the main question the study is designed to answer.
to prove suspicious-looking mucosa on NBI has a bladder tumor on histopathology..
Measured: At the time of TURBT
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Dec 2024
- Study start28 Dec 2024
- Primary completion30 Mar 2025 (estimated)
- Study completion30 Mar 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Transition Cell CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Armed Forces Institute of Urology, Rawalpindi
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Azmat ullah, Armed Forces Institute of Urology, Rawalpindi
- Investigators
- azmat ullah, consultant urologist, Principal investigator, armed forces institute of urology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06729346
- Sponsor's protocol ID
- Trg-1/IRB/2024/023
- Status last verified
- Dec 2024
- First submitted
- 7 Dec 2024
- Last updated
- 29 Jan 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Histopathology report
Study at a glance
From the registry record, last updated by the sponsor on 29 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Can Narrow-band Imaging Detect CIS/Tumor in Normally Looking Bladder Mucosa on White Light Cystoscopy During Transurethral Resection of Bladder Tumor?
- ClinicalTrials.gov ID
- NCT06729346
- Acronym / sponsor ID
- Trg-1/IRB/2024/023
- Conditions
- Transition Cell Cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Armed Forces Institute of Urology, RawalpindiUniversity, hospital or other
- Study start
- 28 Dec 2024 (actual)
- Primary completion
- 30 Mar 2025 (estimated)
- Study completion
- 30 Mar 2025 (estimated)
- First posted
- 11 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
As every urologist does transurethral resection of bladder tumor. So there are instances in which the operating surgeon is not sure whether the normal-looking mucosa or the inflammatory changes are really benign or if we are missing the CIS/bladder cancer.
Detailed description
This is basically the observational study. in which we want to clarify that the normal-looking mucosa on white light cystoscopy is normal in reality or we are missing CIS/bladder tumor.
Study design
- Observational model
- Other
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- any patient who presented with armed forces institute of urology with bladder tumor .
Key inclusion criteria (2 listed)
- any patient with bladder tumor
- -
Key exclusion criteria (1 listed)
- any patient whose age is less than 18 years any patient whose age is more than 75 years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
to prove suspicious-looking mucosa on NBI has a bladder tumor on histopathology..
Time frame: At the time of TURBT
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jan 2025.
- Individual participant dataSharing planned: Yes. Histopathology report
Related trials for Transition Cell Cancer
Active, not recruitingPhase 1
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
Advanced Solid Tumor, Metastatic Colorectal Carcinoma
Active, not recruitingPhase 1
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
Non-Small-Cell Lung Cancer
Active, not recruitingPhase 1/2
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
NSCLC
Enrolling by invitation
VR-PAT During Home Burn Dressings - Multisite
Burns, Acute Pain
Recruiting
The MedMemos Study: Promoting Adherence to Medications in Pediatric Bone Marrow Transplant Patients
Hematopoietic Cell Transplant
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
ullah contact
azmat ullah, consultant urologist principal investigator
armed forces institute of urology
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Transition Cell Cancer, run by Armed Forces Institute of Urology, Rawalpindi at 2 sites in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 29 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact azmat ullah, consultant urologist (+923329354338, azmatdawar254@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
to prove suspicious-looking mucosa on NBI has a bladder tumor on histopathology.. (time frame: At the time of TURBT). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jan 2025.